The company claims that the Sensohaler technology will help doctors to understand the efficacy of medication and help drug providers learn how their products perform early on in clinical trials.
The Sensohaler comprises a microphone sensor and a processor for signal analysis that can sit in or on an inhaler. It accurately measures and monitors key performance characteristics - such as flowrate, inhaled volume and peak inspiratory flowrate, and confirms events such as the firing of a breath actuation mechanism (BAM) and delivery of the formulation through the airway of the device.
The technique is completely non-invasive, having no effect on the airflow or the aerosolisation performance of the inhaler and - if required - could be imperceptible to the user.
A feasibility study using the Sensohaler demonstrated the accuracy of the technology on a range of devices and inhaler types. It proved with two different inhaler types that the flowrate accuracy is on par with that of a thermal mass flowmeter.
Sagentia’s Iain Simpson said: ’Non-compliance in inhaled drug delivery is a big issue - providing direct feedback to users will help reinforce correct usage and also assist clinicians in working with their patients to improve management of their disease.’
AI-generated medical responses need monitoring, study finds
This would negate most of the benefit of using AI in the first place, rather like the Locomotive Act 1865 that required any self-propelled road...